OncoMed Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own OncoMed Pharmaceuticals Inc.
PRIMECAP Odyssey Aggressive Growth Fund
3,763,700
9.77%
1,400
0.08%
06/30/2018
Vanguard Investment Series Plc - US Opportunities Fund
1,800,000
4.68%
0
0.13%
06/30/2018
Vanguard Total Stock Market Index Fund
603,265
1.57%
0
0%
07/31/2018
Candriam Equities L - Biotechnology
380,000
0.99%
0
0.06%
07/31/2018
Vanguard Extended Market Index Fund
287,555
0.75%
0
0%
07/31/2018
Columbia Variable - Wanger US Equities Fund
209,000
0.54%
-5,300
0.04%
03/31/2018
Government Pension Fund - Global (The)
182,356
0.47%
-1
0%
12/31/2017
AXA Rosenberg Eq. Alpha Trust - Global Small Cap Alpha Fund
82,700
0.22%
0
0.03%
03/31/2018
Fidelity Spartan Extended Market Index Fund
79,764
0.21%
0
0%
07/31/2018
Bridgeway Ultra Small Company Market Fund
75,000
0.2%
-8,000
0.04%
12/31/2017
| Address |
800 Chesapeake Drive
Redwood City California 94063
United States
|
|
Employees
|
- |
| Website |
http://www.oncomed.com |
| Updated |
09/14/2018 |
| OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer's growth, resistance, recurrence and metastasis. The company was founded by Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA. |
